drugset / Trial / NCT06761846
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC/GEJ adenocarcinoma after D2 or broader radical resection. After enrolling in the study, the subjects receive Sintilimab combined with oxaliplatin+Tegafur, Gimeracil and Oteracil Potassium Capsules (SOX) or oxaliplatin+Capecitabine (XELOX) , in which the combined chemotherapy is up to 8 cycles, and the total course of treatment was 16 cycles. The following-up of subjects includes adverse events、disease status、living conditions and the quality of life.
Timeline
- Start
- 2025-01-17
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Gimeracil | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | S-1 | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Subject | oteracil | Small molecule | — | — |